JP2008162987A5 - - Google Patents

Download PDF

Info

Publication number: JP2008162987A5
Authority: JP; Japan
Prior art keywords: preparation; tissue; regeneration; anp; repair
Prior art date: 2006-12-31
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

JP2006357531A

Other languages

English (en)

Japanese (ja)

Other versions

JP2008162987A (ja

JP5010913B2 (ja

Filing date

2006-12-31

Publication date

2010-02-25

2006-12-31 Application filed filed Critical

2006-12-31 Priority to JP2006357531A priority Critical patent/JP5010913B2/ja

2006-12-31 Priority claimed from JP2006357531A external-priority patent/JP5010913B2/ja

2008-07-17 Publication of JP2008162987A publication Critical patent/JP2008162987A/ja

2010-02-25 Publication of JP2008162987A5 publication Critical patent/JP2008162987A5/ja

2012-08-29 Application granted granted Critical

2012-08-29 Publication of JP5010913B2 publication Critical patent/JP5010913B2/ja

Status Expired - Fee Related legal-status Critical Current

2026-12-31 Anticipated expiration legal-status Critical

Links

101710004775 NPPA Proteins 0.000 claims description 24
102100015107 NPPA Human genes 0.000 claims description 24
238000002360 preparation method Methods 0.000 claims description 24
210000001519 tissues Anatomy 0.000 claims description 20
210000003491 Skin Anatomy 0.000 claims description 18
230000008929 regeneration Effects 0.000 claims description 15
238000011069 regeneration method Methods 0.000 claims description 15
230000003698 anagen phase Effects 0.000 claims description 14
230000003779 hair growth Effects 0.000 claims description 14
210000000988 Bone and Bones Anatomy 0.000 claims description 13
101700054791 DIUH Proteins 0.000 claims description 12
210000000056 organs Anatomy 0.000 claims description 11
108010082834 Brain Natriuretic Peptide Proteins 0.000 claims description 9
200000000020 tissue injury Diseases 0.000 claims description 7
210000000845 Cartilage Anatomy 0.000 claims description 6
239000004480 active ingredient Substances 0.000 claims description 6
230000001746 atrial Effects 0.000 claims description 6
101710040071 NPPC Proteins 0.000 claims description 5
210000004304 Subcutaneous Tissue Anatomy 0.000 claims description 5
IUCCYQIEZNQWRS-DWWHXVEHSA-N Ularitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@@H](N)[C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 IUCCYQIEZNQWRS-DWWHXVEHSA-N 0.000 claims description 5
239000003795 chemical substances by application Substances 0.000 claims description 5
239000002537 cosmetic Substances 0.000 claims description 5
230000001172 regenerating Effects 0.000 claims description 5
101700017856 vnp Proteins 0.000 claims description 5
206010056370 Congestive cardiomyopathy Diseases 0.000 claims description 4
102000014961 Protein Precursors Human genes 0.000 claims description 4
108010078762 Protein Precursors Proteins 0.000 claims description 4
108010001957 Ularitide Proteins 0.000 claims description 4
102400001282 Urodilatin Human genes 0.000 claims description 4
201000010046 dilated cardiomyopathy Diseases 0.000 claims description 4
OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 claims description 4
239000000126 substance Substances 0.000 claims description 4
206010022114 Injury Diseases 0.000 claims description 3
206010003210 Arteriosclerosis Diseases 0.000 claims description 2
206010007558 Cardiac failure chronic Diseases 0.000 claims description 2
239000003085 diluting agent Substances 0.000 claims description 2
239000000945 filler Substances 0.000 claims description 2
230000000414 obstructive Effects 0.000 claims description 2
210000004400 Mucous Membrane Anatomy 0.000 claims 1
239000000654 additive Substances 0.000 claims 1
230000000996 additive Effects 0.000 claims 1
238000004113 cell culture Methods 0.000 claims 1
-1 excipient Substances 0.000 claims 1
101700017069 ANOP Proteins 0.000 description 21
239000000203 mixture Substances 0.000 description 13
210000004027 cells Anatomy 0.000 description 12
230000000694 effects Effects 0.000 description 11
239000003102 growth factor Substances 0.000 description 10
200000000019 wound Diseases 0.000 description 8
230000017423 tissue regeneration Effects 0.000 description 7
102100005377 BMP2 Human genes 0.000 description 5
101700000123 BMP2 Proteins 0.000 description 5
201000004384 alopecia Diseases 0.000 description 5
239000003814 drug Substances 0.000 description 5
229940079593 drugs Drugs 0.000 description 5
230000003676 hair loss Effects 0.000 description 5
210000004748 cultured cells Anatomy 0.000 description 4
210000004877 mucosa Anatomy 0.000 description 4
210000004165 Myocardium Anatomy 0.000 description 3
230000017531 blood circulation Effects 0.000 description 3
OIRDTQYFTABQOQ-GAWUUDPSSA-N 9-β-D-XYLOFURANOSYL-ADENINE Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@H](O)[C@H]1O OIRDTQYFTABQOQ-GAWUUDPSSA-N 0.000 description 2
OIRDTQYFTABQOQ-SXVXDFOESA-N Adenosine Natural products Nc1ncnc2c1ncn2[C@@H]3O[C@@H](CO)[C@H](O)[C@@H]3O OIRDTQYFTABQOQ-SXVXDFOESA-N 0.000 description 2
101700008793 BNP Proteins 0.000 description 2
239000002126 C01EB10 - Adenosine Substances 0.000 description 2
206010007710 Cartilage injury Diseases 0.000 description 2
206010017711 Gangrene Diseases 0.000 description 2
ZFMITUMMTDLWHR-UHFFFAOYSA-N Loniten Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 2
229960003632 Minoxidil Drugs 0.000 description 2
208000002847 Surgical Wound Diseases 0.000 description 2
229960005305 adenosine Drugs 0.000 description 2
102000004965 antibodies Human genes 0.000 description 2
108090001123 antibodies Proteins 0.000 description 2
230000027455 binding Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
230000022159 cartilage development Effects 0.000 description 2
230000010261 cell growth Effects 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
239000006071 cream Substances 0.000 description 2
230000003013 cytotoxicity Effects 0.000 description 2
231100000135 cytotoxicity Toxicity 0.000 description 2
239000002792 enkephalinase inhibitor Substances 0.000 description 2
238000005755 formation reaction Methods 0.000 description 2
238000009472 formulation Methods 0.000 description 2
230000035876 healing Effects 0.000 description 2
239000007943 implant Substances 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
239000006210 lotion Substances 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
239000000463 material Substances 0.000 description 2
238000000034 method Methods 0.000 description 2
239000003595 mist Substances 0.000 description 2
239000003607 modifier Substances 0.000 description 2
239000003921 oil Substances 0.000 description 2
235000019198 oils Nutrition 0.000 description 2
230000002980 postoperative Effects 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
238000011084 recovery Methods 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
230000000451 tissue damage Effects 0.000 description 2
231100000827 tissue damage Toxicity 0.000 description 2
YOFPFYYTUIARDI-LURJTMIESA-N (2S)-2-aminooctanedioic acid Chemical group OC(=O)[C@@H](N)CCCCCC(O)=O YOFPFYYTUIARDI-LURJTMIESA-N 0.000 description 1
239000005541 ACE inhibitor Substances 0.000 description 1
101700029358 ANF39 Proteins 0.000 description 1
229940116904 ANTIINFLAMMATORY THERAPEUTIC RADIOPHARMACEUTICALS Drugs 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
101700029446 CNP Proteins 0.000 description 1
RZMKWKZIJJNSLQ-UHFFFAOYSA-M Carpronium chloride Chemical compound [Cl-].COC(=O)CCC[N+](C)(C)C RZMKWKZIJJNSLQ-UHFFFAOYSA-M 0.000 description 1
229950003631 Carpronium chloride Drugs 0.000 description 1
210000003169 Central Nervous System Anatomy 0.000 description 1
206010009192 Circulatory collapse Diseases 0.000 description 1
102000006311 Cyclin D1 Human genes 0.000 description 1
108010058546 Cyclin D1 Proteins 0.000 description 1
229940030606 DIURETICS Drugs 0.000 description 1
210000004207 Dermis Anatomy 0.000 description 1
210000002615 Epidermis Anatomy 0.000 description 1
102100007405 FGF7 Human genes 0.000 description 1
101700033323 FGF7 Proteins 0.000 description 1
DBEPLOCGEIEOCV-WSBQPABSSA-N Finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
206010017076 Fracture Diseases 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
102100019269 KRT15 Human genes 0.000 description 1
101710026208 KRT15 Proteins 0.000 description 1
229920001850 Nucleic acid sequence Polymers 0.000 description 1
229940074726 OPHTHALMOLOGIC ANTIINFLAMMATORY AGENTS Drugs 0.000 description 1
241000700159 Rattus Species 0.000 description 1
206010072736 Rheumatic disease Diseases 0.000 description 1
101700074681 STX2 Proteins 0.000 description 1
102100003001 STX2 Human genes 0.000 description 1
206010027699 Skin injury Diseases 0.000 description 1
241001504592 Trachurus trachurus Species 0.000 description 1
206010068760 Ulcers Diseases 0.000 description 1
229940029983 VITAMINS Drugs 0.000 description 1
229940021016 Vitamin IV solution additives Drugs 0.000 description 1
206010052428 Wound Diseases 0.000 description 1
239000006096 absorbing agent Substances 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000012190 activator Substances 0.000 description 1
230000032683 aging Effects 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
201000005794 allergic hypersensitivity disease Diseases 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
239000002280 amphoteric surfactant Substances 0.000 description 1
239000003945 anionic surfactant Substances 0.000 description 1
230000001396 anti-anti-diuretic Effects 0.000 description 1
230000000844 anti-bacterial Effects 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
239000003899 bactericide agent Substances 0.000 description 1
239000002876 beta blocker Substances 0.000 description 1
239000007844 bleaching agent Substances 0.000 description 1
229950005472 carpronium Drugs 0.000 description 1
239000003093 cationic surfactant Substances 0.000 description 1
230000022131 cell cycle Effects 0.000 description 1
230000022534 cell killing Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
230000003749 cleanliness Effects 0.000 description 1
238000005336 cracking Methods 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
239000000539 dimer Substances 0.000 description 1
201000010099 disease Diseases 0.000 description 1
201000009910 diseases by infectious agent Diseases 0.000 description 1
239000002934 diuretic Substances 0.000 description 1
210000002253 embryonic cardiomyocyte Anatomy 0.000 description 1
239000003925 fat Substances 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
229960004039 finasteride Drugs 0.000 description 1
239000003205 fragrance Substances 0.000 description 1
230000012010 growth Effects 0.000 description 1
239000007952 growth promoter Substances 0.000 description 1
229920000591 gum Polymers 0.000 description 1
101500022875 human Atrial natriuretic peptide Proteins 0.000 description 1
229920002674 hyaluronan Polymers 0.000 description 1
229960003160 hyaluronic acid Drugs 0.000 description 1
229910052588 hydroxylapatite Inorganic materials 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
239000003446 ligand Substances 0.000 description 1
230000003020 moisturizing Effects 0.000 description 1
239000005445 natural product Substances 0.000 description 1
229930014626 natural products Natural products 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
239000002674 ointment Substances 0.000 description 1
230000033667 organ regeneration Effects 0.000 description 1
230000011164 ossification Effects 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
239000003002 pH adjusting agent Substances 0.000 description 1
230000001575 pathological Effects 0.000 description 1
239000000813 peptide hormone Substances 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000002335 preservative Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000001737 promoting Effects 0.000 description 1
239000003223 protective agent Substances 0.000 description 1
201000004681 psoriasis Diseases 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
230000002829 reduced Effects 0.000 description 1
238000007788 roughening Methods 0.000 description 1
230000037390 scarring Effects 0.000 description 1
239000003352 sequestering agent Substances 0.000 description 1
238000004904 shortening Methods 0.000 description 1
230000036560 skin regeneration Effects 0.000 description 1
MAKUBRYLFHZREJ-JWBQXVCJSA-M sodium;(2S,3S,4R,5R,6R)-3-[(2S,3R,5S,6R)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylate Chemical compound [Na+].CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@H](O)[C@H]1O MAKUBRYLFHZREJ-JWBQXVCJSA-M 0.000 description 1
238000005507 spraying Methods 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
230000000699 topical Effects 0.000 description 1
231100000397 ulcer Toxicity 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
229930003231 vitamins Natural products 0.000 description 1
229920003169 water-soluble polymer Polymers 0.000 description 1
230000037303 wrinkles Effects 0.000 description 1

JP2006357531A 2006-12-31 2006-12-31 心房利尿ホルモンファミリー分子を活性物質として含有する組織再生製剤また該製剤をもちいる組織再生方法、および心房利尿ホルモンファミリー分子を活性物質として含有する発毛、増毛、育毛剤および皮膚組織修復改善剤また該製剤を用いる発毛、増毛、育毛促進方法および皮膚組織修復改善方法 Expired - Fee Related JP5010913B2 (ja)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
JP2006357531A JP5010913B2 (ja)	2006-12-31	2006-12-31	心房利尿ホルモンファミリー分子を活性物質として含有する組織再生製剤また該製剤をもちいる組織再生方法、および心房利尿ホルモンファミリー分子を活性物質として含有する発毛、増毛、育毛剤および皮膚組織修復改善剤また該製剤を用いる発毛、増毛、育毛促進方法および皮膚組織修復改善方法

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP2006357531A JP5010913B2 (ja)	2006-12-31	2006-12-31	心房利尿ホルモンファミリー分子を活性物質として含有する組織再生製剤また該製剤をもちいる組織再生方法、および心房利尿ホルモンファミリー分子を活性物質として含有する発毛、増毛、育毛剤および皮膚組織修復改善剤また該製剤を用いる発毛、増毛、育毛促進方法および皮膚組織修復改善方法

Publications (3)

Publication Number	Publication Date
JP2008162987A JP2008162987A (ja)	2008-07-17
JP2008162987A5 true JP2008162987A5 (ko)	2010-02-25
JP5010913B2 JP5010913B2 (ja)	2012-08-29

Family

ID=39692940

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2006357531A Expired - Fee Related JP5010913B2 (ja)	2006-12-31	2006-12-31	心房利尿ホルモンファミリー分子を活性物質として含有する組織再生製剤また該製剤をもちいる組織再生方法、および心房利尿ホルモンファミリー分子を活性物質として含有する発毛、増毛、育毛剤および皮膚組織修復改善剤また該製剤を用いる発毛、増毛、育毛促進方法および皮膚組織修復改善方法

Country Status (1)

Country	Link
JP (1)	JP5010913B2 (ko)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2457581B1 (en)	2009-07-23	2014-01-08	Igisu Co., Ltd.	Composition comprising cnp or bnp for external preparation for skin for the treatment of dermatitis
EP2471546B1 (en)	2009-08-27	2015-11-25	Kyoko Endo	Therapeutic agent for rhinitis
DK2666475T3 (da) *	2011-01-21	2017-11-20	Igisu Co Ltd	Terapeutisk middel til skaldethed
JPWO2016194855A1 (ja) *	2015-05-29	2018-06-07	株式会社イギス	環状ペプチド並びに該環状ペプチドを含む医薬、外用剤および化粧料

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2488348A1 (en) *	2002-07-31	2004-02-05	Conjuchem Inc.	Long lasting natriuretic peptide derivatives
JP2004224730A (ja) *	2003-01-23	2004-08-12	Univ Nihon	ヒト心房性ナトリウム利尿ペプチド含有薬剤

2006
- 2006-12-31 JP JP2006357531A patent/JP5010913B2/ja not_active Expired - Fee Related

Publication	Publication Date	Title
JP5735965B2 (ja)	2015-06-17	充填剤および線維芽細胞成長培地を組合せる注射用組成物
EP1779862B1 (de)	2010-05-19	Erythropoietin in subpolycythämischen dosen zur behandlung von diabetes
KR101678621B1 (ko)	2016-11-22	스피큘을 포함하는 피부관리용 화장품 조성물 및 이의 제조방법
EP2156843A2 (de)	2010-02-24	Verwendung von niedrig dosiertem Erythropoietin zur Behandlung von akuter oder chronischer Niereninsuffizienz und zur Behandlung von Wunden
CN113301910B (zh)	2023-02-03	肽组分的皮肤更新和愈合混合物及其用途
TW200409653A (en)	2004-06-16	Compositions containing peptide copper complexes and soft tissue fillers, and methods related thereto
KR20180041645A (ko)	2018-04-24	성장인자 및 아미노산을 포함하는 것을 특징으로 하는 발모 촉진제
JP2008162987A5 (ko)	2010-02-25
JP5144690B2 (ja)	2013-02-13	Ｐｌｇｆ−１を含む医薬品及び化粧品組成物
JP5553284B2 (ja)	2014-07-16	皮膚の老化や瘢痕の治療剤
KR20210075051A (ko)	2021-06-22	하이드로젤 패치를 포함하는 상처 또는 흉터 치료용 조성물
KR20130109850A (ko)	2013-10-08	재조합 인간 골형성 단백질을 활성성분으로 함유하는 피부조직 재생용 키트
JP5010913B2 (ja)	2012-08-29	心房利尿ホルモンファミリー分子を活性物質として含有する組織再生製剤また該製剤をもちいる組織再生方法、および心房利尿ホルモンファミリー分子を活性物質として含有する発毛、増毛、育毛剤および皮膚組織修復改善剤また該製剤を用いる発毛、増毛、育毛促進方法および皮膚組織修復改善方法
KR101917026B1 (ko)	2019-01-24	피부 주름 개선 또는 예방용 화장료 조성물
US8703704B2 (en)	2014-04-22	Method for growing, restoring and regenerating hair
KR101453219B1 (ko)	2014-10-22	생체 접합용 조성물
KR20170029241A (ko)	2017-03-15	성장인자 및 아미노산을 포함하는 것을 특징으로 하는 발모 촉진제
KR102342784B1 (ko)	2021-12-23	탈모 방지 및 발모촉진용 색조 화장 조성물
CN113473963A (zh)	2021-10-01	化妆品/皮肤病学组合物
KR101921246B1 (ko)	2018-11-22	탈모 방지 및 양모를 위한 헤어 필러 조성물 및 그 제조 방법
Klewin-Steinböck et al.	2021	Potential usefulness of enamel matrix derivative in skin and mucosal injury treatment
KR102324076B1 (ko)	2021-11-08	엘라스틴 및 콜라겐 유도를 이용한 피부 주름 및 탄력 개선 효과 조성물
Jáñez et al.	2019	Was It Gold What Shone? Platelet-Rich Plasma Applications, Outcomes and Security Considerations
RU2599034C1 (ru)	2016-10-10	Применение плацентарного препарата лаеннек для подготовки к пластической операции и реабилитация после пластической операции
KR20200062071A (ko)	2020-06-03	지방 생성을 자극하는 펩타이드, 조성 및 방법